GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All comparisons

Semaglutide vs Tirzepatide in India — Class-Level Comparison

Last reviewed 12 May 2026 · India-specific clinical evidence

The short answer

Semaglutide is a single-agonist GLP-1 receptor drug; tirzepatide is a dual GIP/GLP-1 agonist. In India, semaglutide is available as Ozempic, Wegovy, Rybelsus, and 10+ Indian generic brands; tirzepatide is currently only available as Mounjaro. Tirzepatide produces ~50% more weight loss on average (~22% vs ~15% at maximum doses) but costs 3–5× more in India. The molecule choice is mechanism-vs-cost, with the brand choice within each class adding further variability.

Not sure which one applies to you?

Take the 5-minute Indian-guideline eligibility check.

Take the free assessment →

Semaglutide vs Tirzepatide — at a glance

AttributeSemaglutideTirzepatide
MechanismGLP-1 receptor agonistGIP + GLP-1 dual agonist
Indian brand optionsOzempic, Wegovy, Rybelsus (oral), 10+ genericsMounjaro only
Generic availabilityYes, since ~2024–2025No — patented through ~2030
Indications (DCGI approved)T2D, Obesity, Cardiovascular event reductionT2D + Obesity
Dose range (weekly injection)0.25 – 2.4 mg2.5 – 15 mg
Oral formulationYes (Rybelsus 3, 7, 14 mg daily)No (injection only)
Mean weight loss (max dose, non-diabetic)~14.9% (STEP-1, 68 wk)~22.5% (SURMOUNT-1, 72 wk)
Mean HbA1c reduction (max dose, T2D)~1.8% (SUSTAIN)~2.6% (SURPASS)
Approx. monthly price (India)₹1,290 (generic) – ₹16,400 (Wegovy)₹14,000 – ₹27,500
Cardiovascular outcomes evidenceSELECT trial — 20% MACE reductionSURPASS-CVOT pending
Real-world Indian experience~3+ years~1 year

Efficacy — what the trials show

Semaglutide

Semaglutide is the most evidence-supported GLP-1 molecule globally. Pivotal trials: STEP-1 to STEP-8 (weight loss across populations), SUSTAIN-1 to SUSTAIN-10 (T2D), SELECT (cardiovascular outcomes), SOUL (oral semaglutide cardiovascular trial 2024), PIONEER program (oral). Combined enrolment >50,000 patients. Mean weight reduction 10–15%, mean HbA1c 1.4–1.8%. The SELECT trial outcomes (cardiovascular MACE reduction in non-diabetics) is unique to this class.

Tirzepatide

Tirzepatide’s SURMOUNT (obesity) and SURPASS (T2D) programs are smaller but consistently show greater efficacy than semaglutide. SURMOUNT-1: ~22.5% weight loss at 15 mg. SURMOUNT-3: continued loss when stacked on lifestyle. SURPASS-2: head-to-head superiority over semaglutide in T2D. The dual GIP/GLP-1 mechanism is the proposed efficacy driver. Long-term outcomes data (cardiovascular, oncological) is still maturing.

Cost in India (2026)

Semaglutide

In India, the semaglutide price range spans from ₹1,290/month (Indian generics like Sundae, Noveltreat) up to ₹16,400/month (Wegovy 2.4 mg dose). Ozempic sits around ₹5,660–9,100. This breadth — same molecule, 10×+ price variance — makes semaglutide the most accessible GLP-1 class in India.

Tirzepatide

Tirzepatide in India is only available as Mounjaro: ₹14,000–27,500/month. The 5 mg starter dose ≈ ₹14,000; 15 mg target dose ≈ ₹25,000+. No generics. Patent expiry not expected until late this decade, so the price gap is structural for several years.

Side effects

Semaglutide

Class-level semaglutide side effects: nausea 16–44% (dose-dependent), diarrhea 11–32%, vomiting 8–25%. Most peak during titration. Rare but characterized: pancreatitis, gallbladder events, retinopathy in poorly-controlled T2D, theoretical thyroid C-cell signal. Long history means real-world safety is well-mapped.

Tirzepatide

Class-level tirzepatide side effects: nausea 18–28%, diarrhea 16–23%, vomiting 6–13%. Generally similar to or slightly milder than semaglutide despite higher efficacy. The dual agonist mechanism may temper GLP-1-driven nausea. Less characterized: long-term GIP-receptor effects in humans (the GIP arm is less studied than GLP-1 alone).

Which one should you consider?

Pick Semaglutide if

  • ✓You want the option to start cheap (Indian generic) and switch up later
  • ✓You have established cardiovascular disease (SELECT data)
  • ✓You’re considering an oral option (Rybelsus)
  • ✓You prefer a molecule with longer real-world track record
  • ✓You’re cost-sensitive

Pick Tirzepatide if

  • ✓You want maximum weight loss in a single therapy
  • ✓You’ve already tried semaglutide without sufficient effect
  • ✓You have severe obesity (BMI ≥35) where larger weight loss is clinically urgent
  • ✓You can afford the higher monthly cost

Frequently asked questions

Is tirzepatide a "stronger semaglutide"?+
Not quite — they’re structurally different molecules with different receptor activity. Semaglutide activates only the GLP-1 receptor; tirzepatide activates both GLP-1 and GIP receptors. The dual activation appears to produce stronger weight loss and slightly better glucose control. Calling tirzepatide "stronger" is shorthand for the efficacy difference, but mechanistically they’re distinct classes.
Which molecule should I start with as an Indian patient?+
Most Indian endocrinologists recommend starting with semaglutide for several reasons: longer track record, broader brand and price options (Ozempic, Wegovy, generics), and the cardiovascular outcomes evidence (SELECT). If response after 6 months is insufficient — i.e. <5% weight loss or HbA1c not at target — switching to tirzepatide is a common next step.
Is the difference between semaglutide and tirzepatide worth the 3× price?+
Depends on your goal. For maximum weight loss (e.g., BMI ≥35, urgent reduction needed), tirzepatide’s additional 7–8% weight reduction can be clinically significant — the equivalent of bariatric-adjacent outcomes. For modest weight loss in BMI 28–32 patients, semaglutide at maximum dose produces 80% of the benefit at one-third the cost. The price-vs-efficacy curve flattens for less severe obesity.
Are Indian generic semaglutides as effective as Ozempic and Wegovy?+
Bioequivalence is confirmed for DCGI-approved generics, meaning the molecule is identical and pharmacokinetics fall within 90% confidence intervals. Clinical effect should match Ozempic/Wegovy at equivalent doses. Real-world experience is more limited than for the originator brands, but no major safety or efficacy gaps have emerged for the regulated DCGI-approved generics.
Will tirzepatide become available as a generic in India soon?+
Not soon. Eli Lilly’s tirzepatide patents in India extend into the late 2020s. Once expired, Indian manufacturers (Sun Pharma, Dr Reddy’s, Cipla, etc) will likely launch generics following the semaglutide playbook, dropping prices significantly. Expect this 2028–2030 timeframe.
Can I take both semaglutide and tirzepatide for greater effect?+
No — combining two GLP-1-active drugs is not recommended. The mechanisms overlap, dose-related side effects compound, and there’s no clinical evidence of additional benefit. Use one at a time, optimized to your goals. Switching from one to the other (with appropriate washout) is fine; stacking is not.
Which is better for fatty liver (NAFLD/MASH)?+
Both molecules show benefit for liver fat reduction; tirzepatide has slightly stronger data in MASH trials (~28% liver fat reduction in SYNERGY-NASH at high doses vs ~22% with semaglutide in similar studies). Either is reasonable for an Indian patient with NAFLD as a secondary indication. Choose primarily on weight-loss and diabetes goals; the liver benefit comes along with the weight reduction.

Related comparisons

Ozempic vs Mounjaro

Ozempic vs Mounjaro in India — For Diabetes and Weight

Ozempic vs Wegovy

Ozempic vs Wegovy in India — Which One Do You Actually Need?

Mounjaro vs Wegovy

Mounjaro vs Wegovy in India — Which Loses More Weight?

Find out which one fits your profile

The 5-minute Indian-guideline assessment uses your BMI, comorbidities, and lab values (optional) to recommend an evidence-based starting point.

Start the free assessment →

Information based on DCGI-approved labelling, peer-reviewed trials (STEP, SUSTAIN, SURMOUNT, SURPASS, SELECT), and ESI India clinical guidelines. Always consult a qualified medical practitioner before starting or switching therapy. Both molecules referenced here are Schedule H drugs in India.